Cargando…

HSP90 Inhibitor Ganetespib Enhances the Sensitivity of Mantle Cell Lymphoma to Bruton’s Tyrosine Kinase Inhibitor Ibrutinib

Mantle cell lymphoma (MCL) is a highly aggressive and heterogeneous B-cell lymphoma. Though Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has shown great efficacy as a single agent for MCL treatment, the real-world use of ibrutinib is still subject to limitations. Our previous study has shown t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Ziwen, Wang, Zhixin, Tu, Zhigang, Liu, Hanqing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204102/ https://www.ncbi.nlm.nih.gov/pubmed/35721157 http://dx.doi.org/10.3389/fphar.2022.864194

Ejemplares similares

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021)

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma
por: Wang, Michael L., et al.
Publicado: (2023)

Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells
por: Gomez-Casal, Roberto, et al.
Publicado: (2015)

Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models
por: Lin, Shu-Fu, et al.
Publicado: (2017)

Corrigendum: Effects of Hsp90 Inhibitor Ganetespib on Inhibition of Azole-Resistant Candida albicans
por: Yuan, Rui, et al.
Publicado: (2021)

Transient HSP90 inhibition enhances the sensitivity of mantle cell lymphoma to poly (ADP-ribose) polymerase (PARP) inhibitors
por: Shi, Chaowen, et al.
Publicado: (2023)

Synergistic Activity of the HSP90 Inhibitor Ganetespib With Lapatinib Reverses Acquired Lapatinib Resistance in HER2-Positive Breast Cancer Cells
por: Ye, Min, et al.
Publicado: (2021)

HSP-90 Inhibitor Ganetespib is Synergistic with Doxorubicin in Small Cell Lung Cancer
por: Lai, Chien-Hao, et al.
Publicado: (2013)

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
por: He, Suqin, et al.
Publicado: (2014)

The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy
por: Castellani, Francesca, et al.
Publicado: (2020)

Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2022)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
por: Zhu, Zhen, et al.
Publicado: (2020)

The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force
por: Ratain, Mark J., et al.
Publicado: (2022)

Role of Ganetespib, an HSP90 Inhibitor, in Cancer Therapy: From Molecular Mechanisms to Clinical Practice
por: Youssef, Mahmoud E., et al.
Publicado: (2023)

Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer
por: Zucha, Muhammad Ary, et al.
Publicado: (2015)

Ibrutinib, a Bruton’s tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma
por: Wang, Jin, et al.
Publicado: (2017)

The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
por: Smith, Donald L., et al.
Publicado: (2014)

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
por: Proia, David A., et al.
Publicado: (2012)

The HSP90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
por: Lazenby, M., et al.
Publicado: (2015)

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
por: Lang, Julie E., et al.
Publicado: (2022)

The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
por: Ping, Lingyan, et al.
Publicado: (2017)

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers
por: Yang, Xuedong, et al.
Publicado: (2019)

Activity of the Heat Shock Protein 90 Inhibitor Ganetespib in Melanoma
por: Wu, Xinqi, et al.
Publicado: (2013)

P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA
por: Shah, B., et al.
Publicado: (2022)

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling
por: Proia, David A., et al.
Publicado: (2011)

Design, synthesis and evaluation of a series of potential prodrugs of a Bruton’s tyrosine kinase (BTK) inhibitor
por: Xiao, Zhou-Peng, et al.
Publicado: (2023)

Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
por: Sinha, Meenal, et al.
Publicado: (2023)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
por: Jain, Neeraj, et al.
Publicado: (2023)

Cost-effectiveness and value of information analyses of Bruton’s tyrosine kinase inhibitors in the treatment of relapsed or refractory mantle cell lymphoma in the United States
por: Alrawashdh, Neda, et al.
Publicado: (2022)

Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer
por: London, Cheryl A., et al.
Publicado: (2011)

Artesunate, as an Hsp90 inhibitor, inhibits the proliferation of Burkitt’s lymphoma cells by inhibiting AKT and ERK
por: Yuan-Ce, Li, et al.
Publicado: (2023)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes
por: Wei, Li, et al.
Publicado: (2016)

Therapeutic effect of ibrutinib, a selective Bruton’s tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves’ orbitopathy
por: Park, Hyun Young, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
por: Wang, Haoran, et al.
Publicado: (2022)

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL
por: Chen, Timothy L., et al.
Publicado: (2021)

Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
por: HE, SUQIN, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_81ubfh5asbfv38m90bqib0r5lf